AU2003240729B2 - MUC-1 antigen with reduced number of VNTR repeat units - Google Patents

MUC-1 antigen with reduced number of VNTR repeat units Download PDF

Info

Publication number
AU2003240729B2
AU2003240729B2 AU2003240729A AU2003240729A AU2003240729B2 AU 2003240729 B2 AU2003240729 B2 AU 2003240729B2 AU 2003240729 A AU2003240729 A AU 2003240729A AU 2003240729 A AU2003240729 A AU 2003240729A AU 2003240729 B2 AU2003240729 B2 AU 2003240729B2
Authority
AU
Australia
Prior art keywords
muc
vntr
cells
plasmid
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003240729A
Other languages
English (en)
Other versions
AU2003240729A1 (en
Inventor
Neil Burden
Jonathan Henry Ellis
Paul A. Hamblin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU2003240729A1 publication Critical patent/AU2003240729A1/en
Application granted granted Critical
Publication of AU2003240729B2 publication Critical patent/AU2003240729B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2003240729A 2002-05-24 2003-05-23 MUC-1 antigen with reduced number of VNTR repeat units Ceased AU2003240729B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0212046.7A GB0212046D0 (en) 2002-05-24 2002-05-24 Vaccines
GB0212046.7 2002-05-24
PCT/EP2003/005594 WO2003100060A2 (en) 2002-05-24 2003-05-23 Muc-1 antigen with reduced number of vntr repeat units

Publications (2)

Publication Number Publication Date
AU2003240729A1 AU2003240729A1 (en) 2003-12-12
AU2003240729B2 true AU2003240729B2 (en) 2007-12-20

Family

ID=9937394

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003240729A Ceased AU2003240729B2 (en) 2002-05-24 2003-05-23 MUC-1 antigen with reduced number of VNTR repeat units

Country Status (20)

Country Link
US (1) US20060251665A1 (enExample)
EP (1) EP1527177A2 (enExample)
JP (1) JP2005526520A (enExample)
KR (1) KR20050004211A (enExample)
CN (1) CN100408682C (enExample)
AR (1) AR039846A1 (enExample)
AU (1) AU2003240729B2 (enExample)
BR (1) BR0311211A (enExample)
CA (1) CA2485816A1 (enExample)
GB (1) GB0212046D0 (enExample)
IL (1) IL165156A0 (enExample)
IS (1) IS7526A (enExample)
MX (1) MXPA04011527A (enExample)
NO (1) NO20044947L (enExample)
NZ (1) NZ536668A (enExample)
PL (1) PL374569A1 (enExample)
RU (1) RU2303069C2 (enExample)
TW (1) TW200407426A (enExample)
WO (1) WO2003100060A2 (enExample)
ZA (1) ZA200409445B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0212036D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
GB0304634D0 (en) * 2003-02-28 2003-04-02 Glaxo Group Ltd Vaccines
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
ES2476990T3 (es) 2003-11-12 2014-07-15 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sistema para tratar y prevenir cáncer de mama
WO2005046622A2 (en) 2003-11-12 2005-05-26 Therion Biologics Corporation Custom vectors for treating and preventing pancreatic cancer
EP1848804B1 (en) * 2005-01-28 2011-10-05 Ramot at Tel Aviv University, Ltd. Anti-muc1 alpha beta antibodies
WO2010002478A2 (en) 2008-07-03 2010-01-07 University Of Georgia Research Foundation, Inc. Glycopeptide and uses thereof
WO2011156751A2 (en) * 2010-06-11 2011-12-15 University Of Georgia Research Foundation, Inc. Immunogenic vaccine
CN106215179A (zh) * 2010-06-11 2016-12-14 乔治亚大学研究基金公司 免疫原性疫苗
JP2014518841A (ja) * 2011-02-24 2014-08-07 オンコシレオン インク． アジュバントを備えたｍｕｃ１ベースのグリコリポペプチドワクチン
CA2954892A1 (en) * 2016-01-19 2017-07-19 Pfizer Inc. Immunogens derived from tumor-associated antigens or nucleic acid molecules encoding the immunogens
AU2017336269B2 (en) * 2016-09-28 2022-06-16 Bavarian Nordic A/S Compositions and methods for enhancing the stability of transgenes in poxviruses
EP3794042B1 (en) 2018-05-18 2024-03-27 Daiichi Sankyo Co., Ltd. Anti-muc1- exatecan antibody-drug conjugate

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001046228A2 (en) * 1999-12-22 2001-06-28 Glaxo Group Limited Nucleic acid vaccination
WO2003099193A2 (en) * 2002-05-24 2003-12-04 Glaxo Group Limited Vaccines

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101028523A (zh) * 1995-11-30 2007-09-05 德克萨斯州立大学董事会 诊断和治疗肿瘤的方法及组合物
CA2282300C (en) * 1997-02-24 2011-08-02 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen
US6228843B1 (en) * 1999-04-23 2001-05-08 University Technology Corporation Method of using PKC inhibiting compounds to treat vascular disease
WO2001018035A2 (en) * 1999-09-08 2001-03-15 Transgene S.A. Muc-1 derived peptides
WO2001057068A1 (en) * 2000-02-01 2001-08-09 The Austin Research Institute Mucin-1 derived antigens and their use in immunotherapy
US20020142047A1 (en) * 2001-01-19 2002-10-03 Johnson Mark E. Microsphere delivery of mucin peptides
US7125663B2 (en) * 2001-06-13 2006-10-24 Millenium Pharmaceuticals, Inc. Genes, compositions, kits and methods for identification, assessment, prevention, and therapy of cervical cancer
EP1572918B1 (en) * 2002-04-15 2011-10-19 Oncothyreon Inc. Synthetic glyco-lipo-peptides as vaccines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001046228A2 (en) * 1999-12-22 2001-06-28 Glaxo Group Limited Nucleic acid vaccination
WO2003099193A2 (en) * 2002-05-24 2003-12-04 Glaxo Group Limited Vaccines

Also Published As

Publication number Publication date
JP2005526520A (ja) 2005-09-08
TW200407426A (en) 2004-05-16
ZA200409445B (en) 2006-02-22
KR20050004211A (ko) 2005-01-12
CA2485816A1 (en) 2003-12-04
MXPA04011527A (es) 2005-09-30
NO20044947L (no) 2005-12-16
RU2303069C2 (ru) 2007-07-20
CN1668746A (zh) 2005-09-14
WO2003100060A3 (en) 2004-02-19
BR0311211A (pt) 2005-03-01
AU2003240729A1 (en) 2003-12-12
PL374569A1 (en) 2005-10-31
IL165156A0 (en) 2005-12-18
GB0212046D0 (en) 2002-07-03
NZ536668A (en) 2007-01-26
IS7526A (is) 2004-11-11
CN100408682C (zh) 2008-08-06
NO20044947D0 (no) 2004-11-12
WO2003100060A2 (en) 2003-12-04
RU2004134331A (ru) 2005-08-27
AR039846A1 (es) 2005-03-02
EP1527177A2 (en) 2005-05-04
US20060251665A1 (en) 2006-11-09

Similar Documents

Publication Publication Date Title
CA2388045C (en) Nucleic acid immunogenic compositions encoding hsp-antigen chimera
AU2006299106A1 (en) Compositions and methods for treating tumors presenting survivin antigens
KR20210104745A (ko) 합성 펩티드 면역원에 대한 면역 자극제로서 인공 무차별적 t 헬퍼 세포 에피토프
JP2008245651A (ja) 改良されたワクチン
PT2155243E (pt) Composição e métodos compreendendo os antigénios klk3, psca ou folh1
US20060251665A1 (en) Vaccines
WO2019101062A9 (zh) 重组疫苗及其应用
WO2000025827A2 (en) Dna molecules encoding muc-1 and use thereof in tumor vaccination
CN100393878C (zh) 疫苗
US20070042047A1 (en) Vaccines
US20060062798A1 (en) Vaccines
US20060147458A1 (en) Vaccines
EP1240317B1 (en) Nucleic acid vaccination
CN121620389A (zh) 一种针对MICA/B靶点的mRNA肿瘤疫苗
CN115819613A (zh) 基于msln前体蛋白构建的嵌合抗原受体免疫细胞制备及其应用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired